The safety and sensitivity of [111In]In-CHX-A′′-DTPA-trastuzumab suggested that it can potentially be used in the clinic as a diagnostic tool for HER2-positive tumors in breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.